{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:02:27Z","timestamp":1789394547761,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018592","name":"Celltrion","doi-asserted-by":"publisher","award":["CT-P16 3.1"],"award-info":[{"award-number":["CT-P16 3.1"]}],"id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40259-026-00800-1","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T09:42:03Z","timestamp":1785663723000},"page":"883-897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin\u00ae and US-Avastin\u00ae in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6790-2679","authenticated-orcid":false,"given":"Taekyung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1091-3642","authenticated-orcid":false,"given":"Heungjo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9051-4738","authenticated-orcid":false,"given":"Hongjae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9370-5338","authenticated-orcid":false,"given":"Keumyoung","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1922-2810","authenticated-orcid":false,"given":"Taehong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7286-7215","authenticated-orcid":false,"given":"Hyungseok","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8408-5907","authenticated-orcid":false,"given":"Min Jung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,2]]},"reference":[{"key":"800_CR1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391\u2013400. https:\/\/doi.org\/10.1038\/nrd1381.","journal-title":"Nat Rev Drug Discov"},{"key":"800_CR2","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335\u201342. https:\/\/doi.org\/10.1056\/NEJMoa032691.","journal-title":"N Engl J Med"},{"key":"800_CR3","unstructured":"US Food and Drug Administration. Biosimilar product information. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information. Accessed 7 Oct 2024."},{"key":"800_CR4","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1182\/blood-2012-04-425744","volume":"120","author":"M Weise","year":"2012","unstructured":"Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, et al. Biosimilars: what clinicians should know. Blood. 2012;120:5111\u20137. https:\/\/doi.org\/10.1182\/blood-2012-04-425744.","journal-title":"Blood"},{"key":"800_CR5","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Reflection paper on a tailored clinical approach in biosimilar development. EMA\/CHMP\/BMWP\/60916\/2025. Draft, consultation 1 April 2025 to 30 September 2025. https:\/\/www.ema.europa.eu\/en\/reflection-paper-tailored-clinical-approach-biosimilar-development. Accessed 1 Dec 2025."},{"key":"800_CR6","unstructured":"US Food and Drug Administration. Increasing the efficiency of biosimilar development programs: reevaluating the need for comparative clinical efficacy studies. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/increasing-efficiency-biosimilar-development-programs-reevaluating-need-comparative-clinical. Accessed 26 Oct 2025."},{"key":"800_CR7","unstructured":"World Health Organization. Guidelines on evaluation of biosimilars. https:\/\/www.who.int\/publications\/m\/item\/guidelines-on-evaluation-of-biosimilars. Accessed 26 Oct 2025."},{"key":"800_CR8","unstructured":"European Medicines Agency. Streamlining development and assessment of biosimilar medicines. https:\/\/www.ema.europa.eu\/en\/news\/streamlining-development-assessment-biosimilar-medicines. Accessed 1 Dec 2025."},{"key":"800_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.7249\/rhq-07-04-03","volume":"7","author":"AW Mulcahy","year":"2018","unstructured":"Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7:3.","journal-title":"Rand Health Q."},{"key":"800_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00280-016-3079-6","volume":"78","author":"K Han","year":"2016","unstructured":"Han K, Peyret T, Marchand M, Quartino A, Gosselin NH, Girish S, et al. Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol. 2016;78:341\u201351. https:\/\/doi.org\/10.1007\/s00280-016-3079-6.","journal-title":"Cancer Chemother Pharmacol"},{"key":"800_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00280-007-0664-8","volume":"62","author":"JF Lu","year":"2008","unstructured":"Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008;62:779\u201386. https:\/\/doi.org\/10.1007\/s00280-007-0664-8.","journal-title":"Cancer Chemother Pharmacol"},{"key":"800_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1053\/j.seminoncol.2003.08.013","volume":"30","author":"MA Cobleigh","year":"2003","unstructured":"Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I\/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 2003;30:117\u201324. https:\/\/doi.org\/10.1053\/j.seminoncol.2003.08.013.","journal-title":"Semin Oncol"},{"key":"800_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40259-019-00340-x","volume":"33","author":"D Shin","year":"2019","unstructured":"Shin D, Lee Y-J, Choi J, Jang IJ, Park M, Lee D. A randomized, double-blind trial comparing the pharmacokinetics of CT-P16, a candidate bevacizumab biosimilar, with its reference product in healthy adult males. BioDrugs. 2019;33:173\u201381. https:\/\/doi.org\/10.1007\/s40259-019-00340-x.","journal-title":"BioDrugs"},{"key":"800_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s40259-022-00552-8","volume":"36","author":"C Verschraegen","year":"2022","unstructured":"Verschraegen C, Andric Z, Moiseenko F, Pikiel J, Zurawski B, Dakhil S, et al. Candidate bevacizumab biosimilar CT-P16 versus European Union reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer: a randomized controlled trial. BioDrugs. 2022;36:749\u201360. https:\/\/doi.org\/10.1007\/s40259-022-00552-8.","journal-title":"BioDrugs"},{"key":"800_CR15","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O\u2019Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748\u201356. https:\/\/doi.org\/10.1200\/JCO.1989.7.11.1748.","journal-title":"J Clin Oncol"},{"key":"800_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit: a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241\u201357. https:\/\/doi.org\/10.1016\/j.cmpb.2005.04.005.","journal-title":"Comput Methods Programs Biomed"},{"key":"800_CR17","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2023. https:\/\/www.R-project.org\/. Accessed 7 Oct 2024."},{"key":"800_CR18","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1023\/A:1011527125570","volume":"28","author":"U Wahlby","year":"2001","unstructured":"Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001;28:231\u201352. https:\/\/doi.org\/10.1023\/A:1011527125570.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"800_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","volume":"35","author":"TM Post","year":"2008","unstructured":"Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35:185\u2013202. https:\/\/doi.org\/10.1007\/s10928-007-9081-1.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"800_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"THT Nguyen","year":"2017","unstructured":"Nguyen THT, Mouksassi MS, Holford N, Al-Huniti N, Freedman I, Hooker AC, et al. Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacometr Syst Pharmacol. 2017;6:87\u2013109. https:\/\/doi.org\/10.1002\/psp4.12161.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"800_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1288308","volume":"14","author":"S Park","year":"2023","unstructured":"Park S, Jung JA, Ju S, Lim HS. Exposure\u2013response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab. Front Pharmacol. 2023;14:1288308. https:\/\/doi.org\/10.3389\/fphar.2023.1288308.","journal-title":"Front Pharmacol"},{"key":"800_CR22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1541-0420.2007.00987_11.x","volume":"64","author":"N Holford","year":"2008","unstructured":"Holford N. Pharmacometrics: the science of quantitative pharmacology. Biometrics. 2008;64:313. https:\/\/doi.org\/10.1111\/j.1541-0420.2007.00987_11.x.","journal-title":"Biometrics"},{"key":"800_CR23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/psp4.12049","volume":"5","author":"S Marshall","year":"2016","unstructured":"EFPIA MID3 Workgroup, Marshall S, Burghaus R, Cosson V, Cheung SYA, Chenel M, et al. Good practices in model-informed drug discovery and development: practice, application, and documentation. CPT Pharmacometr Syst Pharmacol. 2016;5:93\u2013122. https:\/\/doi.org\/10.1002\/psp4.12049.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"800_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-019-03946-8","volume":"85","author":"CSW Li","year":"2020","unstructured":"Li CSW, Sweeney K, Cronenberger C. Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin\u00ae) in patients with advanced non-squamous non-small cell lung cancer. Cancer Chemother Pharmacol. 2020;85:487\u201399. https:\/\/doi.org\/10.1007\/s00280-019-03946-8.","journal-title":"Cancer Chemother Pharmacol"},{"key":"800_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s13318-023-00855-3","volume":"48","author":"JS Owen","year":"2023","unstructured":"Owen JS, Rackley RJ, Hummel MA, Roepcke S, Huang H, Liu M, et al. Population pharmacokinetics of MYL-1402O, a proposed biosimilar to bevacizumab and reference product (Avastin\u00ae) in patients with non-squamous non-small cell lung cancer. Eur J Drug Metab Pharmacokinet. 2023;48:675\u201389. https:\/\/doi.org\/10.1007\/s13318-023-00855-3.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"800_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40261-025-01518-8","volume":"46","author":"Q Hong","year":"2026","unstructured":"Hong Q, Jiao Y, Li D, Ma H, Wu K, Xie L. Population pharmacokinetics of SCT510 (a bevacizumab biosimilar) and Avastin\u00ae in healthy subjects and patients with non-squamous non-small cell lung cancer. Clin Drug Investig. 2026;46:143\u201357. https:\/\/doi.org\/10.1007\/s40261-025-01518-8.","journal-title":"Clin Drug Investig"},{"issue":"Suppl. 10","key":"800_CR27","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1002\/jcph.907","volume":"57","author":"JM Bullock","year":"2017","unstructured":"Bullock JM, Lin T, Bilic S. Clinical pharmacology tools and evaluations to facilitate comprehensive dose finding in oncology: a continuous risk\u2013benefit approach. J Clin Pharmacol. 2017;57(Suppl. 10):S105\u201315. https:\/\/doi.org\/10.1002\/jcph.907.","journal-title":"J Clin Pharmacol"},{"key":"800_CR28","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1002\/sim.10088","volume":"43","author":"M Philipp","year":"2024","unstructured":"Philipp M, Tessier A, Donnelly M, Burger HU, Pigeolet E, Retout S. Model-based bioequivalence approach for sparse pharmacokinetic bioequivalence studies: model selection or model averaging? Stat Med. 2024;43:3403\u201316. https:\/\/doi.org\/10.1002\/sim.10088.","journal-title":"Stat Med"},{"key":"800_CR29","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1111\/bcp.14330","volume":"86","author":"J Kang","year":"2020","unstructured":"Kang J, Eudy-Byrne RJ, Mondick J, Knebel W, Jayadeva G, Liesenfeld K. Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity. Br J Clin Pharmacol. 2020;86:2274\u201385. https:\/\/doi.org\/10.1111\/bcp.14330.","journal-title":"Br J Clin Pharmacol"},{"key":"800_CR30","unstructured":"European Medicines Agency. Biosimilar medicines can be interchanged. https:\/\/www.ema.europa.eu\/en\/news\/biosimilar-medicines-can-be-interchanged. Accessed 1 Dec 2025."},{"key":"800_CR31","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542\u201350. https:\/\/doi.org\/10.1056\/NEJMoa061884.","journal-title":"N Engl J Med"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00800-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00800-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00800-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:02:32Z","timestamp":1789390952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00800-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,2]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["800"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00800-1","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,2]]},"assertion":[{"value":"8 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Taekyung Kim, Keumyoung Ahn, Taehong Park and Hyungseok Baek are employees of Celltrion, Inc., the manufacturer of CT-P16 (Vegzelma\n                      \u00ae\n                      ). Min Jung Chang, Heungjo Kim and Hongjae Lee have received research funding from Celltrion, Inc.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All clinical studies (NCT03247673, CT-P16 1.2, NCT03676192) were conducted in accordance with the ethical principles of the 1964 Declaration of Helsinki and its later amendments. Each protocol was reviewed and approved by the institutional review board or independent ethics committee at every participating site.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all study participants prior to enrolment in each contributing clinical study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The article does not contain any individual person\u2019s identifying data.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The de-identified data that support the findings of this study may be made available from the corresponding author upon reasonable request and subject to approval by Celltrion, Inc.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NONMEM\n                      \u00ae\n                      control streams used for the final population pharmacokinetic model are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualisation: TK, MJC; methodology: TK, HK, HL, MJC; formal analysis and investigation: TK, HK, HL; conduct of the clinical studies and data acquisition: KA, TP, HB; writing (original draft preparation): TK; writing (review and editing): all authors; supervision: MJC; funding acquisition: KA, TP, HB. All authors read and approved the final manuscript.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}